PMID- 28385256
OWN - NLM
STAT- MEDLINE
DCOM- 20171025
LR  - 20181015
IS  - 1876-7591 (Electronic)
IS  - 1876-7591 (Linking)
VI  - 10
IP  - 4
DP  - 2017 Apr
TI  - Systematic CT Methodology for the Evaluation of Subclinical Leaflet Thrombosis.
PG  - 461-470
LID - S1936-878X(17)30169-9 [pii]
LID - 10.1016/j.jcmg.2017.02.005 [doi]
AB  - Subclinical leaflet thrombosis was recently described in a randomized trial of 
      transcatheter aortic valve replacement. It was subsequently demonstrated in a 
      series of registries that this was a commonly observed imaging finding seen in 
      all transcatheter and surgical bioprostheses. The phenomenon has aroused 
      considerable interest due to the as-yet-undefined risk for later clinical events 
      and the possibility of pharmacological intervention with anticoagulation. 
      Subclinical leaflet thrombosis is easily detected noninvasively by technically 
      suitable computed tomography (CT) with a high degree of concordance to 
      transesophageal echocardiography findings. The CT hallmarks were noted to be 
      hypoattenuated leaflet thickening (HALT) associated with reduced leaflet motion 
      (RELM). The combination of HALT and RELM signified hypoattenuation affecting 
      motion, the standardized imaging endpoint used. This paper describes the 
      systematic CT evaluation methodology that was devised during the Portico trial 
      investigation and U.S. Food and Drug Administration submission; it also 
      highlights the need for an ongoing discussion among experts to enable, with the 
      help of the Valve Academic Research Consortium, standardization of reporting of 
      this imaging finding to cater to the present and future needs of clinical trials.
CI  - Copyright (c) 2017 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Jilaihawi, Hasan
AU  - Jilaihawi H
AD  - Heart Valve Center, New York University Langone Medical Center, New York, New 
      York. Electronic address: hasanjilaihawi@gmail.com.
FAU - Asch, Federico M
AU  - Asch FM
AD  - MedStar Cardiovascular Research Network at Washington Hospital Center, Washington 
      DC.
FAU - Manasse, Eric
AU  - Manasse E
AD  - St. Jude Medical, Minnepolis, Minnesota.
FAU - Ruiz, Carlos E
AU  - Ruiz CE
AD  - Hackensack University Medical Center, Hackensack, New Jersey.
FAU - Jelnin, Vladimir
AU  - Jelnin V
AD  - Hackensack University Medical Center, Hackensack, New Jersey.
FAU - Kashif, Mohammad
AU  - Kashif M
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Kawamori, Hiroyuki
AU  - Kawamori H
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Maeno, Yoshio
AU  - Maeno Y
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Kazuno, Yoshio
AU  - Kazuno Y
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Takahashi, Nobuyuki
AU  - Takahashi N
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Olson, Richard
AU  - Olson R
AD  - St. Jude Medical, Minnepolis, Minnesota.
FAU - Alkhatib, Joe
AU  - Alkhatib J
AD  - St. Jude Medical, Minnepolis, Minnesota.
FAU - Berman, Daniel
AU  - Berman D
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Friedman, John
AU  - Friedman J
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Gellada, Norman
AU  - Gellada N
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Chakravarty, Tarun
AU  - Chakravarty T
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Makkar, Raj R
AU  - Makkar RR
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - JACC Cardiovasc Imaging
JT  - JACC. Cardiovascular imaging
JID - 101467978
SB  - IM
EIN - JACC Cardiovasc Imaging. 2017 Jun;10(6):718. PMID: 28595846
MH  - Aortic Valve/*diagnostic imaging/physiopathology/*surgery
MH  - Asymptomatic Diseases
MH  - Bioprosthesis
MH  - Echocardiography, Transesophageal
MH  - Heart Valve Prosthesis
MH  - Heart Valve Prosthesis Implantation/*adverse effects/instrumentation
MH  - Humans
MH  - Predictive Value of Tests
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Thrombosis/*diagnostic imaging/etiology/therapy
MH  - *Tomography, X-Ray Computed
MH  - Transcatheter Aortic Valve Replacement/adverse effects/instrumentation
MH  - Treatment Outcome
OTO - NOTNLM
OT  - TAVI
OT  - TAVR
OT  - aortic stenosis
OT  - aortic valve replacement
OT  - leaflet thrombosis
OT  - transcatheter aortic valve implantation
OT  - transcatheter aortic valve replacement
EDAT- 2017/04/08 06:00
MHDA- 2017/10/27 06:00
CRDT- 2017/04/08 06:00
PHST- 2016/11/15 00:00 [received]
PHST- 2017/02/13 00:00 [revised]
PHST- 2017/02/17 00:00 [accepted]
PHST- 2017/04/08 06:00 [entrez]
PHST- 2017/04/08 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
AID - S1936-878X(17)30169-9 [pii]
AID - 10.1016/j.jcmg.2017.02.005 [doi]
PST - ppublish
SO  - JACC Cardiovasc Imaging. 2017 Apr;10(4):461-470. doi: 10.1016/j.jcmg.2017.02.005.